Published in Hepatitis Weekly, March 7th, 2005
Fendrix is designed to prevent hepatitis B in patients with renal insufficiency, including specific high-risk groups such as pre-hemodialysis and hemodialysis patients from 15 years of age onwards. Hemodialysis patients' immune response is typically lower than in healthy individuals, therefore a need exists for a vaccine with an improved immunogenicity profile to ensure patients are protected against hepatitis B infections.
Fendrix builds on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.